Aduro Biotech Appoints Sylvia R. Wheeler As Senior Vice President, Corporate Affairs And Investor Relations

Aduro Biotech, Inc. today announced the appointment of Sylvia R. Wheeler to the position of senior vice president, Corporate Affairs and Investor Relations. Ms. Wheeler, a veteran biopharmaceutical executive, joins Aduro with over 20 years of experience driving communications strategies and initiatives. In her new role, Ms. Wheeler will be a member of the executive leadership team and will report to Stephen T. Isaacs, chairman, president and chief executive officer of Aduro.

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.